FrancophonIA/ELRC3.0 huggingface dataset:
English: In the 52-week atopic dermatitis dupilumab + TCS study, eczema herpeticum was reported in 0.2 % of the dupilumab + TCS group and 1.9 % of the placebo + TCS group.
Danish: I studiet med dupilumab + TKS på 52 uger ved atopisk dermatitis, blev eczema herpeticum rapporteret hos 0,2 % af gruppen, som fik dupilumab + TKS, og hos 1,9 % af gruppen, som fik placebo + TKS.
English: Hold the syringe in the middle of the syringe body with the needle pointing away from you and pull off the needle cap.
Danish: Hold midt på injektionssprøjtens hoveddel med kanylen pegende væk fra dig og træk kanylehætten af.
English: Very limited data are available in patients with severe renal impairment (see section 5.2).
Danish: Meget begrænsede data er tilgængelige hos patienter med alvorligt nedsat nyrefunktion (se pkt.
English: The efficacy and safety of dupilumab monotherapy in adolescent patients was evaluated in a multicentre, randomised, double-blind, placebo-controlled study (AD-1526) in 251 adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis (AD) defined by Investigator's Global Assessment (IGA) score ≥3 in the overall assessment of AD lesions on a severity scale of 0 to 4, an Eczema Area and Severity Index (EASI) score ≥16 on a scale of 0 to 72, and a minimum body surface area (BSA) involvement of ≥10%.
Danish: Sikkerhed og virkning af monoterapi med dupilumab hos unge patienter blev vurderet i et dobbeltblindet, placebo-kontrolleret, randomiseret multicenterstudie (AD-1526) hos 251 unge patienter i alderen 12-17 år med moderat til svær atopisk dermatitis (AD) defineret ved en score ≥3 på skalaen Investigator's Global Assessment (IGA) i den samlede vurdering af AD-læsioner på en sværhedsgradskala fra 0 til 4, en score ≥16 på Eczema Area and Severity Index (EASI) på en skala fra 0 til 72 og en minimum involvering af legemsoverfladeareal (BSA) på ≥10 %.
English: Table 16: ACQ-5 and AQLQ(S) Responder Rates at Week 52 in QUEST
Danish: Tabel 16: ACQ-5 og AQLQ(S) responsrater ved uge 52 i QUEST
English: • Let your skin dry before injecting.
Danish: • Lad huden tørre inden injektionen.
English: • Read all of the instructions carefully before using the pre-filled pen.
Danish: • Læs nøje hele brugsanvisningen, inden du bruger den fyldte pen.
English: • the Dupixent pre-filled pen
Danish: • Dupixent fyldt pen
English: In the monotherapy studies (SOLO 1 and SOLO 2), across all treatment groups, the mean age was 38.3, the mean weight was 76.9 kg, 42.1% were female, 68.1% were white, 21.8% were Asian, and 6.8% were black.
Danish: I studierne med monoterapi (SOLO 1 og SOLO 2), var gennemsnitsalderen på tværs af alle behandlingsgrupper 38,3 år, gennemsnitsvægten var 76,9 kg, 42,1 % var kvinder, 68,1 % var hvide, 21,8 % var asiatiske, og 6,8 % var sorte.
English: • Then lift the pen up off the skin, your injection is complete.
Danish: • Løft pennen lige op og væk fra huden efter injektionen er gennemført.
English: Step 9: Insert
Danish: Trin 9: Indfør
English: Table 2: List of adverse reactions in atopic dermatitis MedDRA System
Danish: Tabel 2: Liste over bivirkninger ved atopisk dermatitis MedDRA
English: Patients treated with dupilumab who develop conjunctivitis that does not resolve following standard treatment should undergo ophthalmological examination (section 4.8).
Danish: Patienter behandlet med dupilumab, der udvikler conjunctivitis, som ikke forsvinder med standardbehandling, skal have foretaget en oftalmologisk undersøgelse (pkt.
English: Atopic dermatitis patients with comorbid asthma
Danish: Patienter med atopisk dermatitis og komorbid astma
English: 600 mg (two 300 mg injections)
Danish: 600 mg (to 300 mg injektioner)
English: c Responder was defined as a patient with IGA 0 or 1 (“clear” or “almost clear”) with a reduction of
Danish: b Respondent var defineret som en patient med IGA 0 eller 1 (“ingen” eller “næsten ingen”) med en reduktion
English: Dupilumab compared with placebo was evaluated in adult patients with moderate to severe asthma on a medium-to-high dose inhaled corticosteroid and a long acting beta agonist.
Danish: Dupilumab blev sammenlignet med placebo hos voksne patienter med moderat til svær astma, som blev behandlet med mellem til høj dosis inhalationskortikosteroid og en langtidsvirkende betaagonist.
English: These reductions in type 2 inflammatory biomarkers were comparable for the 200 mg Q2W and 300 mg Q2W regimens.
Danish: Disse reduktioner i type 2-inflammatoriske biomarkører var sammenlignelige for behandlingsregimerne med 200 mg hver anden uge og 300 mg hver anden uge.
English: Table 10: ACQ-5 and AQLQ(S) Responder Rates at Week 52 in QUEST
Danish: Tabel 10: ACQ-5 og AQLQ(S) responsrater ved uge 52 i QUEST
English: Figure 1 and Figure 2 show the mean percent change from baseline in EASI and the mean percent change from baseline in NRS, respectively up to week 16.
Danish: Figur 1 og figur 2 viser hhv. den gennemsnitlige procentvise ændring fra baseline i EASI og den gennemsnitlige procentvise ændring fra baseline i NRS op til uge 16.
English: Dupixent is available as 200 mg pre-filled pens in a pack containing 1, 2, 3, or 6 pre-filled pens.
Danish: Dupixent fås som 200 mg fyldte penne i en pakning indeholdende 1, 2, 3 eller 6 fyldte penne.
English: The safety and benefits of Dupixent are not yet known in children with asthma below the age of 12.
Danish: Dupixents sikkerhed og virkning er endnu ikke kendt hos børn under 12 år med astma.
English: • Do not remove the yellow cap until just before you give the injection.
Danish: • Fjern først den gule hætte, lige inden du skal foretage injektionen.
English: A total of 107 adolescents aged 12 to 17 years with moderate to severe asthma were enrolled in QUEST study and received either 200 mg (N=21) or 300 mg (N=18) dupilumab (or matching placebo either 200 mg [N=34] or 300 mg [N=34]) every other week.
Danish: I alt 107 unge i alderen 12-17 år med moderat til svær astma blev inkluderet i QUEST-studiet og fik enten 200 mg (N=21) eller 300 mg (N=18) dupilumab (eller tilsvarende placebo enten 200 mg [N=34] eller 300 mg [N=34]) hver anden uge.
English: Dupixent is used to treat adults and adolescents 12 years and older with moderate-to-severe atopic dermatitis, also known as atopic eczema.
Danish: Dupixent anvendes til at behandle voksne og unge på 12 år og derover med moderat til svær atopisk eksem, også kaldet atopisk dermatitis.
English: d a significantly greater proportion of patients on dupilumab had improvement in pruritus NRS of ≥ 4
Danish: d en betydeligt større andel af patienter i behandling med dupilumab oplevede forbedring i NRS for kløe på ≥ 4
English: Choose a different injection site for each Dupixent injection.
Danish: Skift injektionssted ved hver Dupixent-injektion.
English: After optimizing the OCS dose during the screening period, patients received 300 mg dupilumab (n=103) or placebo (n=107) once every other week for 24 weeks following an initial dose of 600 mg or placebo.
Danish: Efter optimering af oral kortikosteroid-dosis i screeningperioden fik patienterne 300 mg dupilumab (n=103) eller placebo (n=107) en gang hver anden uge i 24 uger efter en startdosis på 600 mg eller placebo.
English: • Keep the syringe(s) out of the reach of children.
Danish: • Injektionssprøjte(r)n(e) skal opbevares utilgængeligt for børn.
English: Do not use the syringe if the expiry date has passed.
Danish: Brug ikke injektionssprøjten, hvis udløbsdatoen er overskredet.
English: Figure 2: Mean percent change from baseline in NRS in SOLO 1a and SOLO 2a (FAS)b
Danish: Figur 2: Gennemsnitlig procentvis ændring fra baseline i NRS i SOLO 1a og SOLO 2a (FAS)b
English: • Never pull back on the plunger rod.
Danish: • Træk aldrig stemplet tilbage.
English: Baseline characteristics are presented in Table 5.
Danish: Karakteristika ved baseline er vist i tabel 5.
English: After the last steady state dose, the median time for dupilumab concentrations to decrease below the lower limit of detection, estimated by population PK analysis, was 9 weeks for the 200 mg Q2W, 1011 weeks for the 300 mg Q2W regimen and 13 weeks for the 300 mg QW regimen.
Danish: Efter den sidste steady state-dosis var den gennemsnitlige tid til reduktion af koncentrationer af dupilumab faldet til under den nedre grænse for detektion, estimeret ved farmakokinetisk populationsanalyse, 9 uger for regimenet 200 mg hver anden uge, 10-11 uger for regimet 300 mg en gang hver anden uge og 13 uger for regimet 300 mg om ugen.
English: • Do not touch the plunger rod until you are ready to inject.
Danish: • Rør ikke stemplet, før du er klar til at injicere.
English: Dupilumab should not be used to treat acute asthma symptoms or acute exacerbations.
Danish: Dupilumab må ikke anvendes til behandling af akutte astmasymptomer eller akutte astmaeksacerbationer.
English: Do not heat the pre-filled pen.
Danish: Opvarm ikke den fyldte pen.
English: In DRI12544 and QUEST, the pre-specified subgroup analyses included blood eosinophils ≥ 150 and ≥ 300 cells/mcL, FeNO ≥ 25 and ≥ 50 ppb.
Danish: I studie DRI12544 og QUEST omfattede den præspecificerede undergruppeanalyse blodeosinofili ≥ 150 og ≥ 300 celler/mikrol og FeNO ≥ 25 og ≥ 50 ppb.
English: Anaphylactic reaction has been reported very rarely in the asthma development program (see section 4.4).
Danish: Anafylaktisk reaktion er rapporteret meget sjældent i astmaudviklingsprogrammet (se pkt.
English: Figure 1: Mean percent change from baseline in EASI in SOLO 1a and SOLO 2a (FAS)b
Danish: Figur 1: Gennemsnitlig procentvis ændring fra baseline i EASI i SOLO 1a og SOLO 2a (FAS)b
English: Duration of Asthma (years), mean ± SD Never smoked, (%)
Danish: Varighed af astma (år), gennemsnit ± SD 22,03 (15,42) Har aldrig røget, (%)
English: The dupilumab group significantly improved patient-reported symptoms, the impact of AD on sleep and health-related quality of life as measured by POEM, SCORAD, and CDLQI scores at 16 weeks compared to placebo.
Danish: I gruppen med dupilumab blev patientrapporterede symptomer, indvirkningen af atopisk dermatitis på søvn og helbredsrelateret livskvalitet betydeligt forbedret som målt ved POEM-, SCORAD- og DLQIscore ved uge 16 sammenlignet med placebo.
English: Placebo ap-value = 0.0003, bp-value = 0.0001, cp-value = 0.0116, dp-value = 0.0024, ep-value <0.0001
Danish: Placebo ap-værdi = 0,0003, bp-værdi = 0,0001, cp-værdi = 0,0116, dp-værdi = 0,0024, ep-værdi <0,0001
English: In a subset of patients with HADS-anxiety or HADS-depression subscale scores ≥ 8 at baseline (the cut-off value for anxiety or depression), a larger proportion of patients in the dupilumab groups achieved HADS-anxiety and HADS-depression scores < 8 at week 16 compared to placebo (See Table 8).
Danish: I en undergruppe af patienter med scorer på underskalaerne HADS-angst eller HADS-depression ≥ 8 ved baseline (grænseværdien for angst eller depression), opnåede en større andel af patienter i grupperne, som fik dupilumab, scorer for HADS-angst og HADS-depression < 8 ved uge 16 sammenlignet med placebo (Se tabel 8).
English: The safety profile of dupilumab in these patients followed through week 16 was similar to the safety profile from studies in adults with atopic dermatitis.
Danish: Dupilumabs sikkerhedsprofil for disse patienter, der blev fulgt til og med uge 16, svarede til den observerede sikkerhedsprofil fra studier med voksne med atopisk dermatitis.
English: Always keep the container out of the reach of children.
Danish: Beholderen skal altid opbevares utilgængeligt for børn.
English: • To help prevent accidental needle injury, each pre-filled syringe has a needle shield that is automatically activated to cover the needle after you have given your injection.
Danish: • Hver fyldt injektionssprøjte er udstyret med et kanylebeskyttelseshylster, der aktiveres automatisk for at afskærme kanylen, efter du har foretaget en injektion, så du kan forebygge utilsigtede skader fra kanylen.
English: Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
Danish: Dupixent er indiceret til behandling af moderat til svær atopisk dermatitis hos voksne og unge fra 12 år og derover, som er kandidater til systemisk behandling.
English: • Do not re-use the pre-filled pen.
Danish: • Genbrug ikke den fyldte pen.
English: The results for VENTURE by baseline biomarkers are presented in the Table 11.
Danish: Resultaterne for VENTURE i forhold til biomarkører ved baseline er vist i tabel 11.
English: Other evaluated outcomes included the proportion of patients with improvement of at least 50 % and 90 % in EASI (EASI-50 and EASI-90, respectively), reduction in itch as measured by the peak pruritus Numerical Rating Scale (NRS), and percent change in the SCORing Atopic Dermatitis (SCORAD) scale from baseline to week 16.
Danish: Andre evaluerede resultater inkluderede andelen af patienter med en forbedring på mindst 50 % og 90 % i EASI (hhv. EASI-50 og EASI-90), reduktion af kløe som målt ved den højeste værdi for kløe på den numeriske vurderingsskala (Numerical Rating Scale, NRS), og den procentvise ændring i skalaen SCORing Atopic Dermatitis (SCORAD) fra baseline til uge 16.
English: The ACQ-5 and AQLQ(S) responder rate results in patients with elevated baseline biomarkers of type 2 inflammation in QUEST at week 52 are presented in Table 16.
Danish: Resultaterne for ACQ-5- og AQLQ(S)-responsrate hos patienter med forhøjet baseline-niveau af biomarkører for type 2-inflammation ved uge 52 i QUEST-studiet er vist i tabel 16.
English: In this subset, the percent change of pruritus NRS from baseline was -51.4 % vs -30.2 % at week 16 and -54.8 % vs -30.9 % at week 52, for the dupilumab 300 mg Q2W and placebo groups respectively.
Danish: I denne undergruppe var den procentvise ændring i NRS for kløe fra baseline -51,4 % vs -30,2 % ved uge 16 og -54,8 % vs -30,9 % ved uge 52, hhv. i gruppen behandlet med dupilumab 300 mg en gang hver anden uge og i gruppen behandlet med placebo.
English: Figure 5: Proportion of adolescent patients with ≥4-point improvement on the pruritus NRS in AD-1526 studya (FAS)b a In the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered non-responders.
Danish: Figur 5: Andel af unge patienter med ≥ 4-point forbedring i NRS for kløe i studie AD-1526a (FAS)b aI de primære analyser af endepunkter for effekt blev patienter, som fik yderligere behandling eller manglede data, betragtet som non-respondenter.
English: Percent of patients whose IGA response at week 36 was maintained within 1 point of baseline in the subset of patients with IGA (0,1) at baseline, n (%) Percent of patients with IGA (0,1) at week 36 in the subset of patients with IGA (0,1) at baseline, n (%) Percent of patients whose peak pruritus
Danish: Procent af patienter for hvilke IGA responset ved uge 36 blev opretholdt inden for 1 point af baseline i undergruppen af patienter med IGA (0,1) ved baseline, n (%)
English: 2 ml solution in a siliconised type-1 clear glass pre-filled syringe with or without needle shield, with a fixed 27 gauge 12.7 mm (½ inch), thin wall stainless steel staked needle.
Danish: 2 ml opløsning i en silikonebehandlet type-1 fyldt injektionssprøjte af gennemsigtigt glas med eller uden kanylebeskyttelseshylster med en fast 12,7 mm (½ tommer) 27 gauge satset kanyle af rustfrit stål.
English: The co-primary endpoints were the difference between baseline (week 0) and week 36 in percent change in EASI from SOLO 1 and SOLO 2 studies baseline and percentage of patients with EASI-75 at week 36 in patients with EASI-75 at baseline.
Danish: De co-primære endepunkter var forskellen mellem baseline (uge 0) og uge 36 i procent ændring i EASI fra SOLO 1 og SOLO 2 studiernes baseline og procentdel af patienter med EASI-75 i uge 36 hos patienter med EASI-75 ved baseline.
English: For adolescents 12 to 17 years of age with atopic dermatitis receiving every other week dosing (Q2W) with either 200 mg (<60 kg) or 300 mg (≥60 kg), the mean ±SD steady state trough concentration of dupilumab was 54.5±27.0 mcg/ml.
Danish: Hos unge i alderen 12-17 år med atopisk dermatitis, som fik doser hver anden uge på enten 200 mg (<60 kg) eller 300 mg (≥60 kg), var den gennemsnitlige laveste steady state-koncentration af dupilumab 54,5±27,0 mikrog/ml.
English: Very rare cases of serum sickness/serum sickness-like reactions have been reported in the atopic dermatitis development program following the administration of dupilumab.
Danish: Meget sjældne tilfælde af serumsygdom/serumsygdomslignende reaktioner er blevet rapporteret i udviklingsprogrammet for atopisk dermatitis efter administrationen af dupilumab.
English: Adolescents
Danish: Unge
English: Number of patients with DLQI ≥4 at baseline DLQI (≥ 4-point improvement), % responders
Danish: Antal patienter med DLQI ≥ 4 ved baseline DLQI (≥ 4-point forbedring), % respondenter
English: After use, place the pre-filled syringe into a puncture-resistant container and discard as required by local regulations.
Danish: Efter brug skal den fyldte injektionssprøjte lægges i en beholder til skarpe genstande og bortskaffes i overensstemmelse med lokale bestemmelser.
English: Dupixent can cause serious side effects, including very rare allergic (hypersensitivity) reactions, including anaphylactic reaction; the signs of allergic reaction or anaphylactic reaction may include:
Danish: Dupixent kan forårsage alvorlige bivirkninger, herunder meget sjældne allergiske (overfølsomheds-) reaktioner, herunder anafylaktisk reaktion.
English: After use, place the pre-filled syringe or the pre-filled pen into a puncture-resistant container and discard as required by local regulations.
Danish: Efter brug skal den fyldte injektionssprøjte eller pen lægges i en beholder til skarpe genstande og bortskaffes i overensstemmelse med lokale bestemmelser.
English: For patients 12 to 17 years of age with atopic dermatitis, the recommended every other week dose is 200 mg (<60 kg) or 300 mg (≥60 kg).
Danish: For patienter i alderen 12-17 år med atopisk dermatitis er den anbefalede dosis 200 mg (< 60 kg) eller 300 mg (≥ 60 kg) hver anden uge.
English: DRI12544 study Dupilumab 200 mg
Danish: DRI12544-studiet Dupilumab 200 mg hver anden uge
English: A. Check expiration date
Danish: A. Tjek udløbsdatoen
English: The long-term safety profile of dupilumab observed in adolescents was consistent with that seen in adults with atopic dermatitis.
Danish: Dupilumabs observerede langtidssikkerhedsprofil hos unge var overensstemmende med den observerede langtidssikkerhedsprofil hos voksne med atopisk dermatitis.
English: Step 1: Remove
Danish: Trin 1: Fjern
English: In this study, 53.1 % of patients had a baseline IGA score of 3 and 46.9 % of patients had a baseline IGA of 4 and 33.6 % of patients received prior systemic immunosuppressants.
Danish: I dette forsøg havde 53,1 % af patienter en IGA score ved baseline på 3, og 46,9 % af patienter havde en IGA på 4 ved baseline, og 33,6 % af patienter havde tidligere fået systemiske immunsuppressiva.
English: Baseline characteristics are presented in Table 11.
Danish: Karakteristika ved baseline er vist i tabel 11.
English: The instructions for the preparation and administration of Dupixent in a pre-filled syringe or in a prefilled pen are given in the package leaflet.
Danish: Instruktioner i forberedelse og administration af Dupixent i en fyldt injektionssprøjte eller fyldt pen findes i indlægssedlen.
English: IGA 0 or 1b, % respondersc
Danish: IGA 0 eller 1b, % respondenterc EASI-50, % respondenterc
English: Figure 1: Proportion of adolescent patients with ≥4-point improvement on the pruritus NRS in AD-1526 studya (FAS)b a In the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered non-responders.
Danish: Figur 1: Andel af unge patienter med ≥ 4-point forbedring i NRS for kløe i studie AD-1526a (FAS)b aI de primære analyser af endepunkter for effekt blev patienter, som fik yderligere behandling eller manglede data, betragtet som non-respondenter.
English: 14.7 % 51.3 %e
Danish: % respondenterc 14,7 % 51,3 %e
English: In the 16-week atopic dermatitis monotherapy clinical studies, serious infections were reported in 1.0 % of patients treated with placebo and 0.5 % of patients treated with dupilumab.
Danish: I de kliniske studier med monoterapi på 16 uger ved atopisk dermatitis blev alvorlige infektioner rapporteret hos 1,0 % af patienter behandlet med placebo og 0,5 % af patienter behandlet med dupilumab.
English: PHARMACEUTICAL PARTICULARS 6.1 List of excipients arginine hydrochloride histidine polysorbate 80 sodium acetate trihydrate glacial acetic acid sucrose water for injections
Danish: FARMACEUTISKE OPLYSNINGER 6.1 Hjælpestoffer argininhydrochlorid histidin polysorbat 80 natriumacetattrihydrat eddikesyre, koncentreret saccharose vand til injektionsvæsker
English: c Patients who received rescue treatment or with missing data were considered as non-responders.
Danish: c Patienter, som fik redningsbehandling eller manglede data, blev betragtet som ikke-respondenter.
English: The safety and benefits of Dupixent are not yet known in children and adolescents with atopic dermatitis below the age of 12.
Danish: Dupixents sikkerhed og virkning er endnu ikke kendt hos børn og unge under 12 år med atopisk dermatitis.
English: Lightly press a cotton ball or gauze on the injection site if you see any blood.
Danish: Pres et stykke vat eller gaze ind mod injektionsstedet, hvis der kommer noget blod.
English: Recommended dose in adult and adolescent patients with asthma For asthma, the recommended dose of Dupixent for adult and adolescents patients (12 years of age and older) is:
Danish: Anbefalet dosis til voksne og unge med astma Den anbefalede dosis af Dupixent ved astma til voksne og unge patienter (12 år eller derover) er:
English: Injection site erythema Injection site oedema Injection site pain Injection site pruritus
Danish: Erytem på injektionsstedet Ødem på injektionsstedet Smerte på injektionsstedet Pruritus på injektionsstedet
English: In a clinical study of AD patients, the effects of dupilumab on the pharmacokinetics (PK) of CYP substrates were evaluated.
Danish: I et klinisk studie med patienter med atopisk dermatitis blev effekterne af dupilumab på CYPsubstraternes farmakokinetik bedømt.
English: In asthma clinical trials, dupilumab treatment markedly decreased FeNO and circulating concentrations of eotaxin-3, total IgE, allergen specific IgE, TARC, and periostin in asthma subjects relative to placebo.
Danish: I kliniske studier med astma medførte dupilumab-behandling et markant fald i FeNO og cirkulerende koncentrationer af eotaxin-3, total IgE, allergenspecifik IgE, TARC samt periostin hos forsøgspersoner med astma sammenlignet med placebo.
English: Very rare cases of serum sickness/serum sickness-like reactions and anaphylactic reaction have been reported following administration of dupilumab (see section 4.4).
Danish: Meget sjældne tilfælde af serumsygdom/serumsygdomslignende reaktioner og anafylaktisk reaktion er blevet rapporteret efter administrationen af dupilumab (se pkt.
English: The ACQ-5 and AQLQ(S) responder rate results in patients with elevated baseline biomarkers of type 2 inflammation in QUEST at week 52 are presented in Table 10.
Danish: Resultaterne for ACQ-5- og AQLQ(S)-responsrate hos patienter med forhøjet baseline-niveau af biomarkører for type 2-inflammation ved uge 52 i QUEST-studiet er vist i tabel 10.
English: Other evaluated outcomes included the proportion of subjects with EASI-50 or EASI-90 (improvement of at least 50% or 90% in EASI from baseline respectively), reduction in itch as measured by the peak pruritus NRS, and percent change in the SCORAD scale from baseline to week 16.
Danish: Andre evaluerede resultater inkluderede andelen af forsøgspersoner med EASI-50 eller EASI-90 (en forbedring på mindst henholdsvis 50 % eller 90 % i EASI fra baseline), reduktion af kløe som målt ved den højeste værdi for kløe på den numeriske vurderingsskala (NRS) og den procentvise ændring i skalaen SCORAD fra baseline til uge 16.